Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) announced it is undertaking a Phase 1 clinical trial on RE104, which is a novel serotonergic substance that could treat postpartum depression. 

32 healthy participants were divided into four ascending-dose cohorts, two of the eight subjects in each cohort receiving a placebo. RE104 not only checked for safety and tolerability with no severe adverse effects but also showed robust and extensive effects with a shorter duration of the psychedelic experience -approx. three to four hours.

The study identified an optimal …

Full story available on